BioCryst Pharmaceuticals BCRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $156.41M-61.5% | $406.56M+155% | $159.4M-2.4% | $163.35M+12.2% | $145.53M+10.6% | ||
| $5.38M-43.5% | $9.52M+335% | $2.19M-21.8% | $2.8M-38.7% | $4.57M-25.0% | ||
| $151.04M-62.0% | $397.03M+153% | $157.21M-2.1% | $160.56M+13.9% | $140.97M+12.4% | ||
| 96.6%-1.1pp | 97.7%-1.0pp | 98.6%+0.3pp | 98.3%+1.4pp | 96.9%+1.5pp | ||
| $60.32M+47.6% | $40.87M-8.4% | $44.6M+2.8% | $43.39M+16.4% | $37.27M-24.6% | ||
| $94.55M-1.3% | $95.78M+15.4% | $83.01M-5.0% | $87.38M+6.0% | $82.47M+2.4% | ||
| $858.01M+487% | $146.17M+12.6% | $129.8M-2.8% | $133.57M+7.4% | $124.31M-8.6% | ||
| -$701.6M-369% | $260.39M+780% | $29.59M-0.7% | $29.79M+40.3% | $21.23M+571% | ||
| -448.6%-513pp | 64%+45.5pp | 18.6%+0.3pp | 18.2%+3.6pp | 14.6%+18.0pp | ||
| $19.78M+39.9% | $14.14M-28.1% | $19.66M-8.9% | $21.58M-8.1% | $23.49M-3.9% | ||
| -$19.21M-55.3% | -$12.37M+29.2% | -$17.46M+25.1% | -$23.3M-13.8% | -$20.47M+4.7% | ||
| -$720.81M-391% | $248.02M+1,945% | $12.13M+87.0% | $6.49M+756% | $758K+103% | ||
| $1M-53.8% | $2.17M+382% | -$769K-155% | $1.4M+93.0% | $726K-9.7% | ||
| -$721.81M-394% | $245.85M+1,806% | $12.9M+154% | $5.09M+15,791% | $32K+100% | ||
| -461.5%-522pp | 60.5%+52.4pp | 8.1%+5.0pp | 3.1%+3.1pp | 0%+20.4pp | ||
| -$2.98-364% | $1.13+1,783% | $0.06+200% | $0.02— | $0.00+100% | ||
| -$700.54M-369% | $260.78M+771% | $29.93M-0.6% | $30.12M+39.7% | $21.56M+613% | ||
| -447.9%-512pp | 64.1%+45.4pp | 18.8%+0.3pp | 18.4%+3.6pp | 14.8%+18.0pp | ||
| -$701.6M-369% | $260.39M+780% | $29.59M-0.7% | $29.79M+40.3% | $21.23M+571% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioCryst Pharmaceuticals's revenue?
- BioCryst Pharmaceuticals (BCRX) generated $885.7M in revenue over the trailing twelve months, up 75.9% year over year.
- Is BioCryst Pharmaceuticals profitable?
- BioCryst Pharmaceuticals is not currently profitable: it reported a net loss of $458.0M over the trailing twelve months, a -51.7% net margin.
- What are BioCryst Pharmaceuticals's profit margins?
- Gross margin is 97.8% and operating margin is -43.1%, with a -51.7% net margin.
- What is BioCryst Pharmaceuticals's earnings per share?
- BioCryst Pharmaceuticals's diluted EPS over the trailing twelve months is $-1.77.
- Where does BioCryst Pharmaceuticals's income statement data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
